^
    Back
    Association details:
    Biomarker:SMAD4 underexpression
    Cancer:Squamous Cell Carcinoma of Head and Neck
    Drug:Erbitux (cetuximab) (EGFR inhibitor)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: D – Preclinical
    New
    Source:
    Cancer Biol Ther
    Title:

    Decreased SMAD4 expression is associated with induction of epithelial-to-mesenchymal transition and cetuximab resistance in head and neck squamous cell carcinoma

    Excerpt:
    In SCC1, SMAD4 KD also caused a significant increase in vimentin mRNA, supporting our hypothesis that SMAD4 down-regulation contributes to EMT in HNSCC…These results suggest that decreased SMAD4 expression is associated with EMT in HNSCC and the functional consequence of this transformation is increased motility and cetuximab resistance.
    DOI:
    10.1080/15384047.2015.1056418